(Total Views: 1856)
Posted On: 04/24/2021 8:26:33 PM
Post# of 148902
A deleted post from Investor's Hub:
Truth4ever responded with a question: Which of your point are conjecture and which are fact?
I answered the question (you can skip the first paragraph as it was responding to the Philippines' House of Representatives hesitation to fully endorse leronlimab. The Chinese, have made numerous incursions into the Philippines' traditional waters. The Philippines is hoping for continued "backup/support" from the US and does NOT want to "rock the boat." Their government is keenly aware of the power BP exerts in our government and their problems with the Chinese are way farther up the "totem Pole" than the approval of leronlimab. The US very recently provided the Philippines with assurance of our continued support - at which point their government breathes a big sigh of relief. This may be why an EUA is being considered/granted re leronlimab.)
I believe the rest of my response is pertinent and perhaps, thought provoking.
*****
On which part? The Chinese incursions are in the international news as is the US government's recent reassurance.
Influx of SE Asian interest in CYDY...that is conjecture. Leronlimab is a very recent addition to their knowledge base. Before April, leronlimab was (conjecture) largely unknown except to a few in the medical/research field. I doubt we had many ( if any) investors from that region. Now events are evolving in such a way that leronlimab could end up better known in that region than our own.
I don't think Lucio Tan, former president Estrada, and the other "in-crowd" that got themselves on the CSP list would overlook such a juicy opportunity and (thanks to the fud) a very reasonable share price. Buying into a biotech with Cytodyn's prospects is a no-brainer. Yes, conjecture and appreciation that these people didn't get where they are by being stupid.
Cytodyn isn't just sending them a drug, it's also giving them ideas. If the US/BP is too stupid to welcome Cytodyn into the fold (where there could be some cooperation), then there are other options. Leronlimab has immense therapeutic and strategic value. The owners of this drug and, in fact, it's headquarters and operations could be centered elsewhere. ( pure conjecture but not illogical). Our total capitalization is cheap compared to Leronlimab's promise.
The USA better grasp what they have or risk losing it. Further, BP better read the tea leaves >> either learn to accept and cooperate or risk leronlimab being controlled from elsewhere with serious vicious consequences to their revenue streams.
Truth4ever responded with a question: Which of your point are conjecture and which are fact?
I answered the question (you can skip the first paragraph as it was responding to the Philippines' House of Representatives hesitation to fully endorse leronlimab. The Chinese, have made numerous incursions into the Philippines' traditional waters. The Philippines is hoping for continued "backup/support" from the US and does NOT want to "rock the boat." Their government is keenly aware of the power BP exerts in our government and their problems with the Chinese are way farther up the "totem Pole" than the approval of leronlimab. The US very recently provided the Philippines with assurance of our continued support - at which point their government breathes a big sigh of relief. This may be why an EUA is being considered/granted re leronlimab.)
I believe the rest of my response is pertinent and perhaps, thought provoking.
*****
On which part? The Chinese incursions are in the international news as is the US government's recent reassurance.
Influx of SE Asian interest in CYDY...that is conjecture. Leronlimab is a very recent addition to their knowledge base. Before April, leronlimab was (conjecture) largely unknown except to a few in the medical/research field. I doubt we had many ( if any) investors from that region. Now events are evolving in such a way that leronlimab could end up better known in that region than our own.
I don't think Lucio Tan, former president Estrada, and the other "in-crowd" that got themselves on the CSP list would overlook such a juicy opportunity and (thanks to the fud) a very reasonable share price. Buying into a biotech with Cytodyn's prospects is a no-brainer. Yes, conjecture and appreciation that these people didn't get where they are by being stupid.
Cytodyn isn't just sending them a drug, it's also giving them ideas. If the US/BP is too stupid to welcome Cytodyn into the fold (where there could be some cooperation), then there are other options. Leronlimab has immense therapeutic and strategic value. The owners of this drug and, in fact, it's headquarters and operations could be centered elsewhere. ( pure conjecture but not illogical). Our total capitalization is cheap compared to Leronlimab's promise.
The USA better grasp what they have or risk losing it. Further, BP better read the tea leaves >> either learn to accept and cooperate or risk leronlimab being controlled from elsewhere with serious vicious consequences to their revenue streams.
(7)
(1)Scroll down for more posts ▼
